The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study
Key result
Intravenous ferric carboxymaltose significantly improved health-related quality of life (KCCQ overall, clinical, and total symptom scores) compared to placebo in patients with CHF (P<0.001).
Why the study?
Does intravenous ferric carboxymaltose improve health-related quality of life in patients with chronic heart failure and iron deficiency?
Population
n=459 patients with chronic heart failure and iron deficiency, with or without anaemia
Comparison
Intravenous ferric carboxymaltose (FCM) vs Placebo
Design
RCT, 2:1
Follow-up
24 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports IV iron repletion for quality-of-life gains in iron-deficient CHF; extends evidence beyond anaemia correction or exercise capacity.
Study Design
Type
RCT (n=459)
Randomization
2:1
Structured PICO
Does intravenous ferric carboxymaltose improve health-related quality of life in patients with chronic heart failure and iron deficiency?
P
Population
n=459 patients with chronic heart failure (reduced left ventricular ejection fraction) and iron deficiency, with or without anaemia
I
Intervention
Intravenous ferric carboxymaltose (FCM)
C
Comparator
Placebo
O
Outcome
Health-related quality of life (HRQoL) assessed using the generic EQ-5D questionnaire and disease-specific Kansas City cardiomyopathy questionnaire (KCCQ) at 4, 12, and 24 weekspatient reported
Main Result
p-value: p=< 0.001
Intravenous ferric carboxymaltose significantly improves health-related quality of life in patients with chronic heart failure and iron deficiency, independent of anaemia status.
Cite This Study
Comín‐Colet et al. (2012) conducted an RCT in chronic heart failure and iron deficiency (n=459). intravenous ferric carboxymaltose vs. placebo was evaluated on mean differences from baseline in KCCQ overall, clinical and total symptom scores (p=< 0.001). Intravenous ferric carboxymaltose significantly improved health-related quality of life (KCCQ overall, clinical, and total symptom scores) compared to placebo in patients with CHF (P<0.001).